June 2018 Issue Table Of Contents

From The Editor

• Where Are The Most Valuable Lessons Learned?

Feature Articles

• How Wild Ideas Fuel Regeneron’s George Yancopoulos
• Industry Explorers Blaze On: Vicki Sato — The Biology Biz
• Chris Garabedian On How To Drive Drug Development

Capitol Perspectives

• Trump Unveils Drug Reforms: Rebates To PBMs At Risk

Companies To Watch

• Sensorion

CEO Corner

• Building A Biotech with A Diversity Mindset

From Principles and Policy to Execution

• Healthcare Is A Global Enterprise In An Insular World

Patient Perspectives

• Empowering Patients At The Time Of Diagnosis

Industry Research

• Is The U.S. Biosimilar Industry Falling Behind?

Inside The Industry

• Breaking Free Of Data Silos Demands A Comprehensive Strategy
• Pharma Needs A New Business Model
• Biopharma Startups Take Advantage Of Open IPO Window
• Pfizer Executives Elaborate On Biosimilar Goals, Challenges
• Being A Multicultural Millennial Female In Pharma Manufacturing
• Mapping The Swedish Precision Medicine Industry Landscape

Leadership Lessons

• The Wrong Answer: Learning To Leverage Opposing Perspectives

Ask The Board

• What Does Every Biopharmaceutical Executive Need To Know About California’s New Drug Pricing Transparency Law, And How Likely Is This To Spread To Other States And Why?
• Clinical Trials Continue To Increase In Complexity And Collect More Data. What Should Sponsors Do To Reduce The Costs Of Clinical Trials?
• Is There A Rise In Activist Investor Activity, And If So, What Is Driving It?